Repligen Corporation (NASDAQ:RGEN) Short Interest Up 28.0% in March

Repligen Corporation (NASDAQ:RGEN) was the target of a significant growth in short interest during the month of March. As of March 31st, there was short interest totaling 5,556,333 shares, a growth of 28.0% from the March 15th total of 4,340,746 shares. Currently, 10.0% of the shares of the stock are short sold. Based on an average daily trading volume, of 887,353 shares, the short-interest ratio is presently 6.3 days.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in RGEN. Wealth Enhancement Advisory Services LLC boosted its position in shares of Repligen by 1.9% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 4,001 shares of the biotechnology company’s stock worth $584,000 after purchasing an additional 75 shares in the last quarter. NewEdge Wealth LLC boosted its position in shares of Repligen by 5.3% during the 4th quarter. NewEdge Wealth LLC now owns 1,492 shares of the biotechnology company’s stock worth $244,000 after purchasing an additional 75 shares in the last quarter. UMB Bank n.a. boosted its position in shares of Repligen by 13.8% during the 4th quarter. UMB Bank n.a. now owns 758 shares of the biotechnology company’s stock worth $124,000 after purchasing an additional 92 shares in the last quarter. Hilltop National Bank boosted its position in shares of Repligen by 8.0% during the 3rd quarter. Hilltop National Bank now owns 1,276 shares of the biotechnology company’s stock worth $171,000 after purchasing an additional 95 shares in the last quarter. Finally, CANADA LIFE ASSURANCE Co boosted its position in shares of Repligen by 0.3% during the 3rd quarter. CANADA LIFE ASSURANCE Co now owns 36,599 shares of the biotechnology company’s stock worth $4,542,000 after purchasing an additional 100 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Analyst Upgrades and Downgrades

RGEN has been the subject of a number of recent research reports. Wall Street Zen cut shares of Repligen from a “buy” rating to a “hold” rating in a research report on Saturday, February 28th. UBS Group reduced their target price on shares of Repligen from $200.00 to $195.00 and set a “buy” rating for the company in a research report on Wednesday, February 25th. KeyCorp restated an “overweight” rating on shares of Repligen in a research report on Wednesday, February 25th. Roth Mkm assumed coverage on shares of Repligen in a research note on Friday. They set a “buy” rating and a $160.00 target price on the stock. Finally, Barclays decreased their target price on shares of Repligen from $175.00 to $145.00 and set an “overweight” rating on the stock in a report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $172.36.

Repligen Trading Up 3.2%

RGEN stock traded up $4.12 during mid-day trading on Friday, hitting $131.21. 1,122,131 shares of the company were exchanged, compared to its average volume of 826,218. The company has a quick ratio of 7.12, a current ratio of 8.37 and a debt-to-equity ratio of 0.26. The firm has a market capitalization of $7.40 billion, a P/E ratio of 154.36, a PEG ratio of 2.58 and a beta of 1.19. The business has a fifty day simple moving average of $124.86 and a 200-day simple moving average of $146.25. Repligen has a 12-month low of $109.66 and a 12-month high of $175.77.

Repligen (NASDAQ:RGEN) last announced its earnings results on Tuesday, February 24th. The biotechnology company reported $0.49 earnings per share for the quarter, topping the consensus estimate of $0.44 by $0.05. The company had revenue of $197.91 million during the quarter, compared to analyst estimates of $192.23 million. Repligen had a net margin of 6.62% and a return on equity of 4.71%. Repligen’s revenue was up 18.1% compared to the same quarter last year. During the same quarter last year, the firm posted $0.44 earnings per share. Repligen has set its FY 2026 guidance at 1.930-2.010 EPS. On average, equities research analysts predict that Repligen will post 1.72 earnings per share for the current fiscal year.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.